O
Oragenics, Inc. (OGEN)
ASE – Real Time Price. Currency in USD
0.59
+0.03 (5.45%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.59
+0.03 (5.45%)
At close: May 12, 2026, 4:00 PM EDT
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
| Name | Position |
|---|---|
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer |
| Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. | Chief Clinical Officer |
| Mr. Charles L. Pope CPA | Executive Chairman |
| Ms. Janet Huffman | CEO, President, CFO, Secretary & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 10-Q | form10-q.htm |
| 2026-05-07 | 8-K | form8-k.htm |
| 2026-04-13 | 8-K | form8-k.htm |
| 2026-03-31 | 8-K | form8-k.htm |
| 2026-03-19 | S-3/A | forms-3a.htm |
| 2026-03-16 | 10-K | form10-k.htm |
| 2026-03-11 | 8-K | form8-k.htm |
| 2026-01-22 | S-3 | forms-3.htm |
| 2026-01-20 | 8-K | form8-k.htm |
| 2025-12-15 | 8-K | form8-k.htm |